Table 2.
Logistic regression analysis results of the influence of DR on ASCVD.
| B | SE | χ 2 | 95%CI | P value | |
|---|---|---|---|---|---|
| DR | |||||
| ASCVD | 0.97 | 0.33 | 8.45 | 2.64 (1.37–5.06) | .00 |
| Model 1 | 0.96 | 0.36 | 7.18 | 2.634 (1.31–5.30) | .00 |
| Model 2 | 0.70 | 0.41 | 2.89 | 2.107 (0.93–4.78) | .07 |
| NPDR | |||||
| ASCVD | 0.70 | 0.38 | 3.44 | 2.01 (0.96–4.19) | .06 |
| Model 1 | 0.67 | 0.40 | 2.79 | 1.98 (0.99–4.35) | .09 |
| Model 2 | 0.42 | 0.47 | 0.80 | 1.52 (0.61–3.78) | .37 |
| PDR | |||||
| ASCVD | 2.49 | 0.78 | 10.29 | 12.05 (2.63–55.12) | .00 |
| Model 1 | 2.34 | 0.81 | 8.40 | 10.69 (2.20–51.87) | .00 |
| Model 2 | 2.10 | 0.84 | 6.20 | 8.18 (1.56–42.81) | .01 |
ASCVD = atherosclerotic cardiovascular disease, DR = diabetic retinopathy, NPDR = nonproliferative DR, PDR = proliferative phase DR; Model 1 was adjusted by age, gender, household registration, family history of ASCVD and duration of diabetes. Model 2 was further adjusted for smoking history, drinking history, education level, physical exercise, obesity (abdominal type, systemic type), history of hypertension, systolic blood pressure, diastolic blood pressure, HbA1c, LDL-C, and eGFR on model 1.